Get ready for a brain revolution! Nexstim, a Finnish powerhouse, is leading the charge in personalized brain health solutions. Their mission? To tackle severe brain diseases and disorders with cutting-edge, non-invasive technology. And they're not just talking the talk; they've developed a game-changer called navigated transcranial magnetic stimulation (nTMS).
This innovative treatment delivers a gentle electrical current to specific brain regions with pinpoint accuracy, offering a safe, painless, and personalized approach. Nexstim's technology is a triple threat, with applications in diagnostics, therapy, and neuroscience research.
But here's where it gets controversial... Nexstim's NBS System 6 is the only nTMS system with the green light from both the FDA and CE for pre-surgical brain mapping. It's a game-changer for treating major depressive disorder and chronic neuropathic pain, and it's got the potential to revolutionize neuroscience research.
And this is the part most people miss: Nexstim's focus is on profitable growth with minimal capital requirements. They're expanding partnerships and maintaining technological leadership with a modular system that's future-proofed for new treatments and indications.
The stage is set for Nexstim's growth, and they're not slowing down. In mid-2024, they signed a letter of intent with Sinaptica Therapeutics, an American startup. The agreement? To co-develop a neuromodulation system, SinaptiStim, for treating Alzheimer's disease. This long-term partnership includes an initial fee, milestone payments, and exclusivity rights for Nexstim's technology in the Alzheimer's field.
But wait, there's more! Nexstim also entered into a development and distribution agreement with Brainlab AG, a German neurosurgery specialist. This agreement, worth up to EUR 5,095 million, aims to develop new neurosurgery solutions based on Nexstim's navigation and intraoperative neuromonitoring technology. It's a win-win, with increased sales of Nexstim systems to third parties expected.
The momentum is building, and it's reflected in Nexstim's half-year report. Net sales for H1 reached EUR 4.5 million, a whopping 41.8% growth! Diagnostics saw a 65.3% increase, therapy sales dipped slightly, and research revenues skyrocketed by 565.7%. Gross margin increased, and EBITDA turned positive. Cash reserves? A healthy EUR 2.7 million.
So, what's driving this growth? Nexstim's global installed base and focus on recurring revenues from service agreements, consumables, and leasing fees. The launch of NBS 6 broadens their product offering and is expected to boost revenues through existing and future partnerships. With Sinaptica, Nexstim is opening doors to the Alzheimer's market, where the need for new therapies is critical.
In his CEO speech, Mikko Karvinen emphasized their focus on profitable net sales growth, and their sales forecast for 2025 looks promising. The following months have been marked by a steady stream of orders, with the launch of NBS 6 for diagnostics in October, following EU and US approvals. This development strengthens Nexstim's position in the US market, despite ongoing customs challenges.
As Nexstim enters its new strategy period (2025-2028), we spoke with CEO Mikko Karvinen about their journey to profitability. With strong growth in diagnostics but a dip in therapy sales during H1, what's the plan to reignite the therapy segment's momentum in 2026?
Mikko shared that their therapy system sales can vary, but recurring revenue gives more stability to future estimates. Nexstim's system stands out with its navigation features, which are likely to become even more crucial in treating brain disorders. This opens new markets for Nexstim's TMS treatments beyond severe depression and chronic neuropathic pain. Technological leadership, ease of use, and scalability are key to their growth strategy through partnerships.
But what about the risks associated with the licensing disputes with Magnus Medical? How are they planning to mitigate potential royalty shortfalls?
In June 2024, Nexstim announced disagreements regarding the licensing of their technology to Magnus Medical. They received additional information about Magnus Medical's commercial product, leading to a disagreement over the use of licensed technology. Nexstim is gathering more information and planning measures to defend their financial interests and intellectual property rights. They don't expect any royalty income from Magnus Medical in 2025 and are not providing an estimate of the total value or financial expectations due to ongoing discussions.
With the Sinaptica collaboration advancing, what are the projected timelines and revenue milestones for the SinaptiStim system's commercialization?
The financial structure of the partnership includes a signing fee, a milestone-based development project, and the sale of clinical and commercial systems. The milestone project and clinical system purchases are defined in the final agreements, which may change during negotiations. The long-term exclusive rights arrangement depends on Sinaptica's payments in 2025 and the signing of final agreements before the end of 2025.
As Nexstim eyes expansion in Asia, which markets are prioritized, and what partnerships are being pursued to accelerate entry?
Diagnostics Business expansion to Asian markets is progressing in close collaboration with Brainlab. Nexstim already has approvals for large APAC markets like India and Australia. They're also exploring expansion possibilities in Japan and China, where their earlier-generation products have been used for research.
With their sights set on continued growth and profitability during the new strategy period (2025-2028), what key performance indicators should investors track most closely in upcoming quarters?
Nexstim is still heavily reliant on new system sales, so growing the number of systems sold is crucial. Recurring revenue growth is a nice addition, with each new system driving some revenue. They've successfully maintained their gross margin levels in a turbulent geopolitical environment through smart operations planning. Managing expenses and cost of goods sold remains an important element of their profitable growth strategy.
Considering their current market position, multiple agreements, and new launches, how confident are they in reaching success?
Despite the tense global political situation, Nexstim's expectations for the future are positive. Their current business is EU and US-focused, but with their new partners, they'll actively expand into the Asian market. Nexstim is committed to developing personalized and effective methods for treating and diagnosing severe brain diseases and disorders. They strongly believe their work will support long-term shareholder value growth through competitive advantages, rapid growth, and improved financial results.
BioStock's news and analysis are independent, but their operations are partly financed by industry companies. This post refers to a company from which BioStock has received funding.
